Evidence map›Paper›PMID 34748204›Full record

ArticleTherapeutic innovation & regulatory science2022

Real World Evidence in Medical Cannabis Research.

Rishi Banerjee, Simon Erridge, Oliver Salazar, Nagina Mangal, Daniel Couch, Barbara Pacchetti, Mikael Hans Sodergren

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic innovation & regulatory science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. A Scoping Systematic Review of Cannabis Use in Endometriosis.The Australian & New Zealand journal of obstetrics & gynaecology · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Observational
  16. Article
  17. An Individual's Lived Experiences of Taking Cannabis-Based Medicinal Products (CBMPs) to Treat Anxiety.International journal of environmental research and public health · 2023
    Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Rishi BanerjeeDepartment of Surgery and Cancer, Imperial College London, London, UK.ORCID http://orcid.org/0000-0002-7785-4317
Simon ErridgeDepartment of Surgery and Cancer, Imperial College London, London, UK.
Oliver SalazarDepartment of Surgery and Cancer, Imperial College London, London, UK.
Nagina MangalDepartment of Surgery and Cancer, Imperial College London, London, UK.
Daniel CouchThe Centre for Medicinal Cannabis, 18 Hanway Street, London, W1T 1UF, UK.
Barbara PacchettiCuraleaf International, London, UK.
Mikael Hans SodergrenDepartment of Surgery and Cancer, Imperial College London, London, UK. m.sodergren@imperial.ac.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWhilst access to cannabis-based medicinal products (CBMPs) has increased globally subject to relaxation of scheduling laws globally, one of the main barriers to appropriate patient access remains a paucity of high-quality evidence surrounding their clinical effects. DISCUSSION: Whilst randomised controlled trials (RCTs) remain the gold-standard for clinical evaluation, there are notable barriers to their implementation. Development of CBMPs requires novel approaches of evidence collection to address these challenges. Real world evidence (RWE) presents a solution to not only both provide immediate impact on clinical care, but also inform well-conducted RCTs. RWE is defined as evidence derived from health data sourced from non-interventional studies, registries, electronic health records and insurance data. Currently it is used mostly to monitor post-approval safety requirements allowing for long-term pharmacovigilance. However, RWE has the potential to be used in conjunction or as an extension to RCTs to both broaden and streamline the process of evidence generation.

conclusionNovel approaches of data collection and analysis will be integral to improving clinical evidence on CBMPs. RWE can be used in conjunction or as an extension to RCTs to increase the speed of evidence generation, as well as reduce costs. Currently, there is an abundance of potential data however, whilst a number of platforms now exist to capture real world data it is important the right tools and analysis are utilised to unlock potential insights from these.

Indexed as

Biomedical ResearchCannabisMedical MarijuanaElectronic Health RecordsHumansRegistriesMedical MarijuanaCannabidiolCannabisCannabis-based medicinal productsDelta(9)-tetrahydrocannabinolMedicinal CannabisReal world evidence

Identifiers

PMID34748204
PMCPMC8688379

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.